NFKK 2014

Thursday September 18


Breakfast seminar:
HemoCue - 
Room: F2

Improved workflow for efficient emergency healthcare
Speaker: Younis Khalid, Chief Physician, Head of Section, Children’s ER,

Drottning Silvias child- and youth hospital

Thermo Fisher Scientific - Room: F1

Copetin – a marker of risk stratification and for early rule out in patients with suspected ACS Speaker: Dr. Joern Ole Vollert, MD., Medical Director, Thermo Fisher Scientific

The latest news in molecular allergology
Speaker: Robert Moverare, Principal Scientist, Thermo Fisher Scientific


Morning Plenary session - Room: F3

Chair: Stefan Jacobsson

Vitamin B12 deficiency. New trends in biomarkers and diagnostic strategies. (301)
Ebba Nexø, Denmark


Coffee and exhibition in the exhibition and poster area


Room: F1

Rare disorders of erythrocytes. The dysregulation of iron and ferritin homeostasis.

Dysregulation of the fine-tuned systemic and/or local iron homeostasis is emerging as an underlying cause of haematological and neurodegenerative diseases. Various forms of hereditary hemochromatosis with low hepcidin expression and iron-refractory iron deficiency anaemia with high hepcidin expression are attributed to mutations affecting the hepcidin-mediated control of the regulation of ferroportin. This session will give an overview of the molecular mechanisms behind rare hereditary disorders of the red blood cell. The aim is to achieve a better understanding of how to use the different available diagnostic tools

Chairs: Linda Fogelstrand and Stefan Jacobsson

10:15 – 10:45 Hereditary hemochromatosis and ferroportin disease (302)
Sandro Altamura, Germany

10:45 – 11:15 Neurological disorders of iron homeostasis: neurodegeneration with brain iron accumulation (NBIA) and neuroferritinopathies (303)
Paolo Arosio,Italy

11:15 – 11:45 Why do we make mistakes in the morphological interpretation of blood slides and how can we improve? (304)
John Burthem, United Kingdom

11:45 – 12:00 Bloodhound Technology™ - Returning to the roots of Hematology (305)
Mark Fellmann, Switzerland

Room: F2

Biomarkers in diagnosis of neurodegenerative diseases

Neurodegenerative disorders constitute a pleiotropic group of diseases that are often hard to distinguish from one another, without knowledge of the underlying pathology, as they often present with similar symptoms. This session will focus on the research frontier of the use of novel biomarkers in the diagnosis of neurodegenerative disorders

Chair:Henrik Zetterberg

10:15-10:45 CSF and plasma biomarkers for Alzheimer’s disease – use for diagnostics and theragnostics (306)
Kaj Blennow, Sweden

10:45-11:15 Emergening molecular diagnostics tools for Alzheimer’s (AD) and other neurodegenerative diseases (307)
Niels H. H. Heegaard,Denmark,

11:15-11:45 Single Molecule Arrays (Simoa) for Ultrasensitive, Multiplexed Detection of Proteins and Nucleic Acids (308)
David Hanlon, United States

Room: F3

The future clinical laboratory as a diagnostic partner

The expansion of our knowledge of disease mechanisms and novel biomarkers is expected to increase the interaction between experts in the clinical laboratory and physicians. This session will discuss what will be expected from the laboratory as a diagnostic partner in future medicine.
Chair: Per Simonsson and Birgitta Kallberg

10:15-10:40 The Cinderellas of health care (309)
Mirja Mindemark, Sweden

10:40-11:05 The future clinical laboratory as diagnosticpartner (310)
Martina Jürs,Denmark

11:05-11:30 Do you read me? - Radio check for clinical chemists. (311)
Per Simonsson, Sweden


Lunch - Exhibition and lunch seminars


Lunch seminar:

Roche Diagnostics AB - Room:F1

Panel discussion: True value of labs within the healthcare system
Tor-Arne Hagve, Specialist in medical biochemistry, physician at the
Laboratory Medical Centre, Akershus University Hospital and professor
at the University of Oslo

Göran Larson Professor, Head of Core Facilities Sahlgrenska Akademin

Robert Sinclair MD, Ph.D, DTM&H, Senior Medical Advisor at Department
of Health Care Region Västra Götaland

Srinivas Uppugunduri Associate professor, Head of Department of
Clinical Chemistry, Center of Laboratory Medicine at County Council of

Kasper Iversen, Ph.D, MD, Cardiologist head physician at Kardiologisk afdeling S, Herlev Hospital

Magnus Göransson General Manager Roche Diagnostics Sweden

Sysmex Sverige - Room: F2

Better staining. Better diagnostic morphology. Three Ways.
Speaker: Henricus Jansen, Marketing Diagnostic Concepts & Lab Solutions, Sysmex Europe


Afternoon Plenary session Room: F3

Chair: Henrik Zetterberg

Blood based biomarkers for Alzheimer’s disease – from case control to endophenotype discovery and from small to large, potentially huge, replication (312)
Simon Lovestone, United Kingdom


Coffee and exhibition in the exhibition and poster area


Room: F1

Laboratory diagnostics of myeloproliferative neoplasms

Our understanding of the molecular changes that lead to the development of different myeloproliferative neoplasms (MPN) have developed rapidly, through the discovery of activating mutations in several genes responsible for the regulation of cell differentiation and proliferation (e.g. the JAK2 gene but also, very recently, of the CALR gene). This has led to new diagnostic and therapeutic opportunities but also new challenges. This session will give a background and update of the laboratory diagnostic of MPN and suggestions on how to integrate new genetic findings in diagnostic algorithms.

Chairs: Linda Fogelstrand and Lars Palmqvist

15:15 - 15:45 Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? (313)

Hans Hasselbalch, Denmark

15:45 - 16:15 Laboratory Diagnostics of Myeloproliferative Neoplasms (314)

Susanne Schnittger,Germany,

16:15 - 16:30 Frequency of CALR mutations and correlation with laboratory findings and clinical outcome in Essential Thrombocythaemia and Primary Myelofibrosis patients (315)

Julia Asp, Sweden

16:30 - 16:45 European JAK2V617Finterlaboratory quality control study carried out by the MPN&MPNR-EURONET (COST ACTION BM0902) (316)

Niels Pallisgaard, Denmark

Room: F2

The Eldjarn Prize

The Lorentz Eldjarn Prize Competition is financed by a Fund established by Professor Lorentz Eldjarn and his wife Torunn in 2009 to award the best article published in Scand J Clin Lab Invest during the five years proceeding the prize year. The Prize Committee has nominated three articles based on the scientific quality of the studies and the clarity of the presentations. The recipients of the prizes will be announced at the Congress Banquet
Chair: Jens P Berg

15:15 - 15:40 Vitamin D and PTH - seasonal and age-related variations. (317)
Monika Christensen,Norway

15:40 - 16:05 Biomarkers of alcohol use and related health risks. (318)
Onni Niemelä,Finland

16:05 - 16:30 Soluble CD163 - a biomarker of macrophage activation in disease. (319)
Holger Jon Møller, Denmark

Room: F3

Organisation of the future clinical laboratory

As laboratory medicine has converged during the past decade, it now possible to merge several aspects of the clinical laboratory. This merger will need differnt IT solutions for different platforms. This session will discuss opportunities and potential problems in this process

Chairs: Birgitta Kallberg and Anders Lindahl

15:15-15:35 Opportunities and pitfalls when integrating laboratory disciplines (320)

Andreas Matussek, Sweden

15:35-15:55 The future of Lab Medicine seen through the eyes of a Niche Supplier. (321)

Jørgen Viktil,Norway

15:55-16:15 Clinical Chemistry towards the future-where to go? (322)

Anders Lindahl, Sweden

16:15-16:30 Panel discussion


SFKK Annual Meeting - Room: F1


Banquet 'Glitter and Glamoure'
Estrad Restaurant, Mässans gata 5, entrance 5.